Ergoteles’s Cytosorbents Corp CTSO Stock Holding History

Ergoteles’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,185	Closed	-$68K	–	1122
2023 Q1	$68K	Sell	20,185 -77,031	-79%	-$231K	﹤0.01%	1119
2022 Q4	$151K	Sell	97,216 -80,287	-45%	-$119K	0.01%	1148
2022 Q3	$241K	Sell	177,503 -25,197	-12%	-$49.2K	0.01%	1088
2022 Q2	$444K	Buy	+202,700	New	+$465K	0.01%	893

Other funds holding CTSO

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Ergoteles's CTSO Position: Q2 2023 in Review

Ergoteles sold out of Cytosorbents Corp (CTSO) in Q2 2023, closing a stake of 20,185 shares — an estimated $68K sold.

Ergoteles first reported a position in CTSO in Q2 2022 and held it in 4 quarters. The position peaked at $444K in Q2 2022. 58 funds tracked by Wall St. Rank hold CTSO as of Q2 2023.

Ergoteles reported no remaining Cytosorbents Corp position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 20,185 Cytosorbents Corp shares in Q2 2023, an estimated $68K.
Ergoteles first reported a position in Cytosorbents Corp in Q2 2022 and held it in 4 quarters.
Ergoteles's Cytosorbents Corp position peaked at $444K in Q2 2022.
58 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.